Is MBX Biosciences, Inc. Common Stock (MBX) a Buy, Sell, or Hold?
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$56.59 USD
-$3.45 (-5.75%)
- Volume
- 1.42M
- Average Volume
- 788.14K
- Market Capitalization
- $1.9B
- P/E Ratio
- -25.72
- Dividend Yield
- 0.00%
- Price Target
- $70.00
- Year High
- $66.55
- Year Low
- $9.63
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $30.79
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Peter Kent Hawryluk |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MBX |
| CUSIP | 55287L101 |
| CIK | 0001776111 |
| Web | https://mbxbio.com |
| Phone | (317) 659-0200 |
| Currency | USD |
| Employees | 63 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 30.79 |
| Quick Ratio | 30.79 |
| Cash Ratio | 3.10 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.71 |
| Price / Cash Flow | -23.82 |
| Price / Book | 6.02 |
Price Target and Rating
| Average Stock Price Forecast | $70.00 |
| High Stock Price Forecast | $88.00 |
| Low Stock Price Forecast | $56.00 |
| Forecast Upside/Downside | -19.16% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.38 |
| Trailing P/E Ratio | -25.72 |
| PEG Ratio | 22.91 |
| P/E Growth | 22.91 |
| Net Income | $-86.97M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -24.50% |
| Return on Assets | -19.13% |
Financials Score
| AltmanZ Score | 79.67 |
| Piotroski Score | 2.00 |
| Working Capital | 433.97M |
| Total Assets | 452.7M |
| Ebit | -86.61M |
| Market Cap | 1.99B |
| Total Liabilities | 14.94M |
Poll Results
About MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) Stock
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291 ... , a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
2026-07-13 16:15:00
CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoerter, current Executive Chairman of the Board, as its new Chairman and Chief Executive Officer. Mr. Hoerter succeeds Kent Hawryluk, who will step down as President, Chief Executive Officer and a member of the Board of Directors. In addition, the Board has appointed John Smither, current Interim Chief Financial Officer, as the Company's new Chief Financial Officer. All leadership changes are effective immediately.
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
2026-07-06 08:38:04
I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks.
2026-06-12 14:32:09
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
2026-06-12 10:43:54
MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide in adults with chronic hypoparathyroidism.
2026-06-12 07:00:00
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial
2026-06-01 08:00:00
CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for once-weekly canvuparatide at the upcoming Endocrine Society's Annual Meeting (ENDO 2026) in Chicago.
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
2026-05-27 15:18:24
MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
2026-05-26 08:00:00
CARMEL, Ind. and BURLINGTON, Mass.
Frequently Asked Questions
-
What is the current MBX Biosciences, Inc. Common Stock (MBX) stock price?
-
MBX Biosciences, Inc. Common Stock(NASDAQ:MBX) stock price is $56.59 in the last trading session. During the trading session, MBX stock reached the peak price of $66.55 while $9.63 was the lowest point it dropped to. The percentage change in MBX stock occurred in the recent session was --5.75% while the dollar amount for the price change in MBX stock was -$-3.45.
-
MBX's industry and sector of operation?
-
The NASDAQ listed MBX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MBX?
-
Andreas Moraitis | Senior Vice President of Clinical Development
Steven L. Hoerter | Executive Chairperson
Michelle Graham | Chief Human Resources Officer
Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications
Chatan Charan | Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls -
How many employees does MBX have?
-
Number of MBX employees currently stands at 63. MBX operates from 11711 N. Meridian Street, Carmel, IN 46032, US.
-
Link for MBX official website?
-
Official Website of MBX is: https://mbxbio.com
-
How do I contact MBX?
-
MBX could be contacted at phone #(317) 659-0200 and can also be accessed through its website. MBX operates from 11711 N. Meridian Street, Carmel, IN 46032, US.
-
How many shares of MBX are traded daily?
-
The average number of MBX shares traded daily for last 3 months was 788.14K.
-
What is the market cap of MBX currently?
-
The market value of MBX currently stands at $1.9B with its latest stock price at $56.59